Sun Pharmaceutical Industries Limited (BOM:524715)
1,845.20
-45.95 (-2.43%)
At close: May 22, 2026
BOM:524715 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 582,201 | 525,784 | 484,969 | 438,857 | 386,545 |
Other Revenue | 22,137 | - | - | - | - |
| 604,338 | 525,784 | 484,969 | 438,857 | 386,545 | |
Revenue Growth (YoY) | 14.94% | 8.42% | 10.51% | 13.53% | 15.39% |
Cost of Revenue | 115,437 | 115,585 | 114,422 | 113,187 | 108,761 |
Gross Profit | 488,901 | 410,200 | 370,547 | 325,670 | 277,784 |
Selling, General & Admin | 114,189 | 100,509 | 95,025 | 83,549 | 73,544 |
Other Operating Expenses | 190,083 | 157,883 | 144,755 | 123,779 | 101,331 |
Operating Expenses | 333,650 | 284,145 | 265,345 | 232,613 | 196,223 |
Operating Income | 155,251 | 126,055 | 105,202 | 93,058 | 81,560 |
Interest Expense | -3,389 | -2,314 | -2,385 | -1,720 | -1,274 |
Interest & Investment Income | - | 12,970 | 11,262 | 5,310 | 7,687 |
Earnings From Equity Investments | -558.7 | -153.5 | -384.1 | -479 | -165.4 |
Currency Exchange Gain (Loss) | 12,402 | 1,855 | 361.3 | -1,261 | 1,540 |
Other Non Operating Income (Expenses) | - | 620.6 | 546.7 | 756.5 | 735.9 |
EBT Excluding Unusual Items | 163,705 | 139,034 | 114,603 | 95,664 | 90,084 |
Merger & Restructuring Charges | - | -3,617 | -739.5 | -643.9 | -563.5 |
Gain (Loss) on Sale of Investments | - | 5,117 | 921.9 | -240.3 | 7.7 |
Gain (Loss) on Sale of Assets | - | -164 | -99.7 | 75.4 | 347.5 |
Asset Writedown | - | -71.3 | -1,564 | -312.5 | -2,179 |
Legal Settlements | - | -58.2 | - | - | -1,563 |
Other Unusual Items | -13,075 | -3,104 | -2,712 | -1,071 | -41,657 |
Pretax Income | 150,630 | 137,368 | 110,495 | 93,605 | 44,648 |
Income Tax Expense | 35,544 | 27,720 | 14,395 | 8,476 | 10,755 |
Earnings From Continuing Operations | 115,087 | 109,648 | 96,100 | 85,129 | 33,893 |
Minority Interest in Earnings | -292.3 | -357.1 | -336.5 | -393.6 | -1,166 |
Net Income | 114,794 | 109,290 | 95,764 | 84,736 | 32,727 |
Net Income to Common | 114,794 | 109,290 | 95,764 | 84,736 | 32,727 |
Net Income Growth | 5.04% | 14.12% | 13.01% | 158.92% | 12.70% |
Shares Outstanding (Basic) | 2,402 | 2,399 | 2,399 | 2,399 | 2,399 |
Shares Outstanding (Diluted) | 2,402 | 2,399 | 2,399 | 2,399 | 2,399 |
Shares Change (YoY) | 0.09% | - | - | - | - |
EPS (Basic) | 47.80 | 45.55 | 39.91 | 35.32 | 13.64 |
EPS (Diluted) | 47.80 | 45.55 | 39.90 | 35.30 | 13.60 |
EPS Growth | 4.94% | 14.16% | 13.03% | 159.56% | 12.40% |
Free Cash Flow | 88,098 | 119,435 | 99,332 | 28,738 | 74,895 |
Free Cash Flow Per Share | 36.68 | 49.78 | 41.40 | 11.98 | 31.21 |
Dividend Per Share | - | 16.000 | 13.500 | 11.500 | 10.000 |
Dividend Growth | - | 18.52% | 17.39% | 15.00% | 33.33% |
Gross Margin | 80.90% | 78.02% | 76.41% | 74.21% | 71.86% |
Operating Margin | 25.69% | 23.97% | 21.69% | 21.20% | 21.10% |
Profit Margin | 19.00% | 20.79% | 19.75% | 19.31% | 8.47% |
Free Cash Flow Margin | 14.58% | 22.72% | 20.48% | 6.55% | 19.38% |
EBITDA | 184,629 | 149,679 | 128,760 | 116,513 | 101,536 |
EBITDA Margin | 30.55% | 28.47% | 26.55% | 26.55% | 26.27% |
D&A For EBITDA | 29,379 | 23,625 | 23,559 | 23,456 | 19,975 |
EBIT | 155,251 | 126,055 | 105,202 | 93,058 | 81,560 |
EBIT Margin | 25.69% | 23.97% | 21.69% | 21.20% | 21.10% |
Effective Tax Rate | 23.60% | 20.18% | 13.03% | 9.05% | 24.09% |
Revenue as Reported | 604,338 | 545,435 | 498,510 | 445,202 | 395,760 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.